Furthermore pre-treatment of GBM E22 cells with IFNβ for 24 hours prior to ZIKV exposure abolished infection as assessed by IF, with infection rates restored by addition of ruxolitinib (Figure S5H). The gene discussed is IFNB1; the disease is infection.